Uploaded April 2026 | Updated September 2026, 2 weeks ago
AI is already reading ECGs, flagging abnormalities on echocardiograms, and assessing CT scans for high-risk findings. But how do you know whether to trust what it tells you?
The uncomfortable truth is that many AI models in cardiology have never been independently validated.
Others perform well on average—but significantly worse for women, older patients, or underrepresented ethnic groups.
In this panel discussion, three experts at the intersection of AI, cardiology, and governance tackle the questions clinicians actually need answered:
What does real-world clinical validation of a cardiac AI tool look like?
What governance structures need to exist before AI can be trusted at scale in cardiology?
The session is moderated by Dr Franz Wiesbauer, CEO and founder of Medmastery.
Panelists
Jack Parker — CEO and co-founder, AIATELLA. Building AI tools to accelerate cardiovascular diagnosis and scale deployment across health systems.
Richard Dasselaar — Chair, AI in Cardiology Working Group (WHO relations). Governance frameworks, lifecycle accountability, and equitable access to cardiac AI globally
0:00 Welcome and introduction
3:19 Meet Richard Desseler: background and passion
7:05 What makes an AI tool trustworthy?
13:16 Hallucinations, regulation, and the risk of omission
23:49 AI in heart failure prediction and screening
28:20 Rapid-fire: distrust signals, transparency, where AI adds value
41:47 Optimism, the Jevons paradox, and finding your niche
54:47 Closing
AI is already reading ECGs, flagging abnormalities on echocardiograms, and assessing CT scans for high-risk findings. But how do you know whether to trust what it tells you?
The uncomfortable truth is that many AI models in cardiology have never been independently validated.
Others perform well on average—but significantly worse for women, older patients, or underrepresented ethnic groups.
In this panel discussion, three experts at the intersection of AI, cardiology, and governance tackle the questions clinicians actually need answered:
What does real-world clinical validation of a cardiac AI tool look like?
What governance structures need to exist before AI can be trusted at scale in cardiology?
The session is moderated by Dr Franz Wiesbauer, CEO and founder of Medmastery.
Panelists
Jack Parker — CEO and co-founder, AIATELLA. Building AI tools to accelerate cardiovascular diagnosis and scale deployment across health systems.
Richard Dasselaar — Chair, AI in Cardiology Working Group (WHO relations). Governance frameworks, lifecycle accountability, and equitable access to cardiac AI globally
0:00 Welcome and introduction
3:19 Meet Richard Desseler: background and passion
7:05 What makes an AI tool trustworthy?
13:16 Hallucinations, regulation, and the risk of omission
23:49 AI in heart failure prediction and screening
28:20 Rapid-fire: distrust signals, transparency, where AI adds value
41:47 Optimism, the Jevons paradox, and finding your niche
54:47 Closing
